2010-022513-26: Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administration of SKP-1052 versus immediate-release terbutaline and placebo tablets in stable Type 1 Diabetes Mellitus Patients |
|
|
| Completed | 2 | 28 | Europe | SKP-1052 Modified-Release Tablets, Bricanyl, SKP-1052, Bricanyl, Bricanyl | SkyePharma AG | Type 1 Diabetes Mellitus | | 05/11 | | |